Global Infertility Drugs Market is valued approximately USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than 6.5% over the forecast period 2022-2029. The term "infertility medicines" refers to a group of pharmaceuticals that are used to treat infertility and improve a person's reproductive health. They can be swallowed or administered intravenously. Gonadotrophins, dopamine agonists, aromatase inhibitors, biguanides, ovulatory stimulants, selective oestrogen receptor modulators (SERMs), and tricyclic antidepressants are a few of the medications that are frequently used to treat infertility. The infertility drugs market is anticipated to expand significantly owing to upsurge in Healthcare Awareness along with increasing aging female population and growing prevalence of stress and life-style disorders among men and women.

The National Center for Drug Abuse Statistics found that during the COVID-19 lockdowns, almost 60.0% of Americans increased their alcohol intake. In a similar vein, according to a study issued by the World Health Organization in 2021, China had more than 300.0 million smokers, or over one-third of the world's population at the time. In China, there were around 26.6% of adults who smoked who were 15 years of age or older. One of the major contributors to hormonal imbalance, polycystic ovarian disease, and weight problems, which have an immediate influence on the embryo and might cause infertility concerns, is a healthy lifestyle. On the other side, over the past 16 years, the percentage of males with a normal total motile sperm count has decreased by around 10%. The evidence is clear: Men today generate less and less healthy sperm than in the past. However, strict regulatory structure that impedes the approval of products stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Infertility Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to menopausal disorders and high concentration of market players or manufacturer's presence. However, Asia Pacific expected to be the fastest growing region owing to rising healthcare expenditures and initiatives by the government to increase the availability of the infertility treatment in the developing nations.

Major market players included in this report are:

Abbott Laboratories

Ferring Pharmaceuticals Inc.

Merck KGaA

Pfizer Inc.

Novartis International AG

Bayer AG

Theramex

Mankind Pharma

Teva Pharmaceuticals Industries

Livzon

Recent Developments in the Market:

In order to sell Genea Biomedx's (Australia) fertility products in the US and Canada, Genea Biomedx (Australia) partnered with Hamilton Thorne in 2020.
In August 2021, Merck introduced Pergoveris Pen in India for the treatment of infertility. The Pergoveris Pen is the first item to ever include both recombinant follicle-stimulating hormone and recombinant luteinizing hormone in a ready-to-use, IVF specialist-prescribed device. A pen with bulk technology that has received international approval offers infertile couples a more secure self-service infertility option.
Global Infertility Drugs Market Report Scope:

Historical Data: 2019-2020-2021

Base Year for Estimation: 2021

Forecast period: 2022-2029

Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

Segments Covered: Drug class, End User, Distribution Channel, Region

Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

Gonadotrophins

Aromatase Inhibitors

Selective Estrogen Receptor Modulators (SERMs)

Biguanides

Other Drug Classes

By End User:

Male

Female

By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Other Distribution Channels

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World